Presentation of the 27-country Hep-CORE 2016 study results

2016 has been an incredibly important year for viral hepatitis. Milestones for global strategies were set through WHO.  This couples with the advent of new, direct acting treatments for hepatitis C which improve outcomes massively to over a 90% likelihood of cure.

Nonetheless, in the WHO European Region, conservative numbers still estimate that 15 million people are living with chronic hepatitis C virus (HCV) infection and that more than 13 million people are infected with chronic hepatitis B virus (HBV). An estimated 171,000 people die each year from viral hepatitis-related causes in this region – and there are major failings in national policy and strategies to effectively combat viral hepatitis. 

Therefore, the ELPA conducted the first-ever pan-European patient-led analysis of gaps and opportunities for improvement in viral hepatitis B and C policies. 27 member patient organizations from 25 European and 2 Mediterranean Basin countries reported on the key indicators for national and subnational hepatitis policy: awareness, prevention, testing and linkage to care, disease monitoring, and treatment.

The final report and results provide the building blocks to identify gaps and successes of specific countries, improve decision-making based on priorities and patient advocacy, and mobilize effective follow-up action in the European context.

The European Liver Patients Association will present the results of this study to member patient organizations and to the media on the occasion of the ELPA Annual Policy Meeting in Berlin, Germany, on the 20th of December 2016.

We look forward to welcoming you to this press conference. Kindly RSVP to this invitation via 
e-mail (d.postulka@ipse.de) or using the attached fax form.

ELPA is able to offer compensation for travel costs. Please let us know if you require this financial assistance.

AGENDA – Tuesday, 20th of December 2016

11:00 am             

Welcome

Tatjana Reic, President, European Liver Patients Association

11:05 am

The Hep-CORE report – methodology and results

Prof.  Jeffrey V. Lazarus, ISGlobal, Hospital Clínic, University of Barcelona

11:35 am

WHO Action Plan - Strategies to eliminate viral hepatitis in Europe

Dr. Sandra Dudareva-Vizule, Robert Koch-Institute, Berlin

11:50 am

Prevalence of HCV and burden of disease – epidemiological and scientific point of view – impact on clinical practice

Prof. Massimo G. Colombo, MD Professor of Gastroenterology, University of Milan, Italy and Chairman of EASL International Liver Foundation

12:15 am

Expectations on politics to meet the hepatitis challenges 

Achim Kautz, Managing director Leberhilfe Projekt gUG and member of the World Health Organization (WHO) strategy group planning committee

12:30 pm              

Question period

 

1:00 pm

Refreshments and time for individual questions and networking